Prime Medicine, Inc. (PRME)
| Market Cap | 629.78M -37.8% |
| Revenue (ttm) | 4.07M -17.9% |
| Net Income | -187.89M |
| EPS | -1.09 |
| Shares Out | 177.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 681,697 |
| Open | 3.550 |
| Previous Close | 3.610 |
| Day's Range | 3.410 - 3.600 |
| 52-Week Range | 2.670 - 6.650 |
| Beta | 2.38 |
| Analysts | Buy |
| Price Target | 7.11 (+100.85%) |
| Est. Earnings | Nov 6, 2026 |
About PRME
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular in... [Read more]
Financial Performance
In 2025, Prime Medicine's revenue was $4.63 million, an increase of 55.28% compared to the previous year's $2.98 million. Losses were -$201.14 million, 2.69% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for PRME stock is "Buy." The 12-month stock price target is $7.11, which is an increase of 100.85% from the latest price.
News
Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units
MONTREAL--(BUSINESS WIRE)--Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces the launch of a proposed private placement financing of subscription receipts for maximum aggregate ...
Prime Medicine doses first patient in PM577a trial
Prime Medicine (PRME) announced that the first patient has been dosed in the company’s global Phase 1/2 clinical trial of PM577a, an investigational in vivo Prime Editor for H1069Q-mutated Wilson…
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutatio...
Prime Medicine Slides: Corporate presentation
Prime Medicine has posted slides in relation to its latest quarterly earnings report, which was published on October 4, 2026.
Prime Medicine announces FDA clearance of IND application for PM647
Prime Medicine (PRME) announced that the FDA has cleared the company’s Investigational New Drug, or IND, application for PM647, an investigational in vivo Prime Editor for Alpha-1 Antitrypsin Deficien...
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine's liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected i...
Prime Medicine Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Prime Editing technology enables versatile and safer gene editing, with ongoing clinical programs in Wilson’s disease and AATD targeting broad patient populations. Regulatory flexibility and efficient delivery platforms support rapid development, with proof-of-concept data expected in 2027 for key programs.
Prime Medicine Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Prime Editing offers broad, precise, and safe genome editing, with clinical progress in CGD, Wilson disease, and Alpha-1 programs. Regulatory flexibility and platform synergies support rapid expansion, while a strong cash position extends runway into 2027.
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therap...
Prime Medicine transferred with Buy rating at Chardan
Chardan analyst Keay Nakae keept a Buy rating on Prime Medicine (PRME) with a $7 price target following a transfer of coverage. The firm cites the potential of the company’s…
BMO starts Prime Medicine at Outperform into 2027 readouts
BMO Capital analyst David Lebowitz initiated coverage of Prime Medicine (PRME) with an Outperform rating and $9 price target The firm views Prime as a “differentiated” next-generation gene editing pla...
Prime Medicine initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Prime Medicine (PRME) with an Outperform rating and $9 price target BMO rolled out coverage on nine biotechnology companies, saying each might be considered a…
Prime Medicine reports Q4 EPS (24c), consensus (26c)
Reports Q4 revenue $1.15M, consensus $1.11M. “We have continued to deliver on the focused strategy we laid out last year,” said Allan Reine, Chief Executive Officer of Prime Medicine (PRME).
Prime Medicine Quarterly report: Q2 2026
Prime Medicine has published its Q2 2026 quarterly earnings report on August 6, 2026.
Prime Medicine Earnings release: Q2 2026
Prime Medicine released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Prime Medicine Slides: Corporate presentation
Prime Medicine has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most p...
TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647
TD Cowen notes that Prime Medicine (PRME) announced a positive binding arbitration resolution with Beam Therapeutics (BEAM) over PM647 in alpha-1 antitrypsin deficiency, confirming PM647 is in Prime’s...
Resolution in favor of Prime has limited impact to Beam, says BofA
BofA analyst Alec Stranahan reiterated a Buy rating and $47 price target on Beam Therapeutics (BEAM) after Prime Medicine (PRME) announced a “positive” resolution to arbitration with Beam Therapeutics...
Prime Medicine reports positive resolution to arbitration with Beam Therapeutics
Prime Medicine (PRME) earlier announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics (BEAM) relating to the parties’ 2019 Collaboration and License Agr...
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
-- Arbitration tribunal declared that PM647 is within Prime Medicine's “Field”, confirming Prime Medicine's right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damag...
Cathie Wood’s ARK Investment buys 206.2K shares of Prime Medicine today
20:12 EDT Cathie Wood’s ARK Investment buys 206.2K shares of Prime Medicine (PRME) today
Prime Medicine Slides: Corporate presentation
Prime Medicine has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Prime Medicine upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Prime Medicine (PRME) to Buy from Neutral with an $8 price target after the company announced that New Zealand’s Medicines and Medical Devices Safety Authority cleared the…
Prime Medicine granted RMAT designation for PM359
Prime Medicine (PRME) announced that the FDA has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to PM359, an investigational autologous Prime Edited hematopoietic stem cell thera...